The development of ovarian follicles and subsequent corpus luteum formation is accompanied by very active angiogenesis.
contrast, VEGF-C mRNA levels increased toward the end of culture. For studying the hormonal regulation of VEGF isotype mRNAs, GL cells were treated with hCG, recombinant human FSH, PGE 2 , as well as 8-bromo-cAMP and 12-O-tetradecanoylphorbol 13-acetate, which activate protein kinase A-and protein kinase C-dependent signaling pathways, respectively. All test agents stimulated the expression of VEGF mRNA levels in a concentration-dependent manner. Timecourse studies indicated that all treatments induced VEGF mRNA levels as early as incubation for 2 h, and the effect was sustained up to 48 h. VEGF-B mRNA levels were not regulated by any of the test agents. However, we found that hCG and 8-bromo-cAMP decreased VEGF-C mRNA levels with a maximal response observed at 24 and 48 h after cellular treatment. We conclude that the mRNAs of VEGF, VEGF-B, and VEGF-C are expressed in human GL cells and that their mRNA steady state levels are regulated in cultured human GL cells in an isotype-specific manner. The differential regulation of VEGF, VEGF-B, and VEGF-C in human GL cells suggests that distinct VEGF isotypes may play different roles during the vascularization of the human ovarian follicle and corpus luteum. (Endocrinology 138: 4748 -4756, 1997) N EW BLOOD vessels are formed by sprouting from the established ones. This process, known as angiogenesis, takes place under both physiological conditions, such as wound healing, ovarian follicular development, corpus luteum (CL) formation, and growth of endometrium during the menstrual cycle, as well as in pathological processes, including solid tumor growth, rheumatoid arthritis, and retinopathies (reviewed in Ref. 1) . Over 50 yr ago Bassett described changes in the vasculature of the developing follicles and CL in rat ovaries during the estrous cycle (2) . More recent studies have demonstrated the angiogenic potential of the CL extracts and follicular fluid (3) (4) (5) as well as granulosa cellconditioned medium (6) . Granulosa cells produce factors, e.g. PGE 2 , transforming growth factor-␤1, basic fibroblast growth factor, and vascular endothelial growth factor (VEGF), that are known to have angiogenic activity (for a review, see Ref. 7) .
VEGF/vascular permeability factor, is an endothelial cell mitogen that has been cloned and extensively characterized by several groups (8 -14 ; reviewed in Ref. 15) . VEGF is a heparin-binding 40-to 46-kDa disulfide-linked dimeric glycoprotein that dissociates upon reduction into two 20-to 23-kDa subunits. (8, 10, 16) . Analysis of the complementary DNA (cDNA) clones revealed that alternative messenger RNA (mRNA) splicing results in the generation of 121-, 165-, 189-, and 206-amino acid (aa)-encoding mRNA forms (17, 18) . Moreover, placental cells and various carcinoma cells of female reproductive tract express a VEGF transcript giving rise to an additional 145-aa isoform (19, 20) . VEGF 121 , VEGF 145 , and VEGF 165 proteins appear to be secreted, whereas the VEGF 189 form is not freely secreted but remains bound to heparan sulfate proteoglycans on the cell surface and in the extracellular matrix (20, 21). VEGF has significant homology with both platelet-derived growth factors A and B, with eight conserved cysteins located at distinct positions in the protein sequence (12, 13) . Placenta growth factor was cloned from human placenta, and it shares a 53% identity with VEGF in the platelet-derived growth factor-like region (22). VEGF is also able to heterodimerize with placenta growth factor (23). Recently, two receptor tyrosine kinases, Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), were shown to bind VEGF with high affinity and to transduce its cellular signal (24 -26). Multiple growth factors, cytokines, hormones, as well as hypoxia regulate the expression of VEGF in various cell cultures (27-33).
VEGF-B and VEGF-C are recently identified endothelial cell growth factors (34 -36) . VEGF-B mRNA splicing results in transcripts encoding a soluble VEGF-B 167 form and a cell surface/extracellular matrix-bound VEGF-B 186 form (37) . VEGF-B isoform monomers are able to form disulfide-linked homodimers, but they are also able to heterodimerize with VEGF (34, 37) . VEGF-C is a secreted protein that stimulates the migration of endothelial cells and is also able to promote their mitogenesis (35, 36) . Similar to VEGF, VEGF-C also increases vascular permeability (38) . VEGF-C exerts its effects via VEGFR-2 and VEGFR-3 (35) , whereas the cellular binding components for VEGF-B remain to be elucidated. VEGFR-2 is expressed by vascular endothelial cells, whereas VEGFR-3 is mainly found in the lymphatic endothelium (25, 39). Interestingly, VEGF-C induced specifically lymphatic, but not vascular, endothelial proliferation and vessel enlargement when overexpressed in the skin of transgenic mice (40) .
As VEGF has been shown to be expressed in primate as well as human granulosa cells and CL (27, 41, 42) , and VEGF-B and VEGF-C are expressed in human ovaries (34 -36) , we have studied the expression of VEGF, VEGF-B, and VEGF-C mRNAs in freshly isolated human granulosa-luteal (GL) cells and the regulation of the steady state levels of these transcripts in cultured GL cells. Our results provide evidence that ovarian GL cells express VEGF, VEGF-B, and VEGF-C and that the distinct VEGF isotypes are differentially regulated in cultured GL cells.
Materials and Methods

Cell culture
Human GL cells were obtained by follicular aspiration from regularly menstruating women undergoing oocyte retrieval for in vitro fertilization (IVF) because of either tubal obstruction or infertility of the spouse. Ovarian stimulation was induced by combining a GnRH analog (Suprecur, Hoechst, Frankfurt am Main, Germany) and human menopausal gonadotropin (Pergonal, Serono Nordic, Vantaa, Finland; or Humegon, Organon, Oss, The Netherlands). Oocyte retrieval was carried out 36 -37 h after hCG (Profasi, Serono; or Pregnyl, Organon) administration at a total dose of 10,000 IU. For each experiment, the cells obtained the same morning from two to four patients were pooled, enzymatically dispersed, and separated from red blood cells by centrifugation through Ficoll-Paque (Pharmacia, Uppsala, Sweden), as previously described (43) . Thereafter, the cells were directly recovered for RNA extraction or plated at a density of 2-5 ϫ 10 5 cells/well on 35-mm six-well dishes (Costar, Cambridge, MA) and cultured in DMEM supplemented with 10% FCS, 2 mm l-glutamine, and antibiotics (Life Technologies, Grand Island, NY) at 37 C in 95% air-5% CO 2 humidified environment. Cell culture media were changed every other day, and hormone treatments were performed between days 1-10 of culture for different time periods. As human placenta and the human choriocarcinoma cell line BeWo are known to express different VEGF isoforms (44) , and as VEGFR-1 is also expressed in JEG choriocarcinoma cells (45), we used human JEG-3 choriocarcinoma cells as a control for the detection of VEGF splicing variants. JEG-3 cells were obtained from American Type Culture Collection (Rockville, MD).
Hormonal treatments of cultured human GL cells
Before hormone treatments, the cells were transferred to DMEM supplemented with 2.5% FCS. To evaluate the effect of the culture age of human GL cells, the cells were treated with 30 or 100 ng/ml purified hCG (CR-127, obtained from the National Hormone and Pituitary Dis- 
RNA extraction and Northern blotting
Total RNA from freshly isolated GL cells and cytoplasmic RNA from cultured GL cells were extracted using the guanidine isothiocyanatecesium chloride method (47) and the modified Nonidet P-40 lysis procedure (48), respectively. RNA was quantitated by absorbance at 260 nm. For Northern blots 17-20 g RNA from freshly isolated human GL cells and 11-15 g RNA from cultured GL cells were size fractionated in 1.5% agarose gels and transferred to Hybond-N nylon membranes (Amersham International, Aylesbury, UK). For dot blots, 1-2 g cytoplasmic RNA were denatured in 7.5% formaldehyde and 6 ϫ SSC (1 ϫ SSC ϭ 0.15 m NaCl and 0.015 m Na citrate, pH 7.0) at 50 C for 30 min and spotted onto nylon membranes using a 96-well Minifold device (Schleicher and Schuell, Keene, NH). The filters were baked for 1 h at 80 C and UV cross-linked with a Reprostar II UV illuminator (Camag, Muttenz, Switzerland) for 6 min before hybridizations.
Reverse transcription-PCR (RT-PCR), Southern blotting, cDNA cloning, and analysis of cDNAs
VEGF cDNAs were synthesized by RT-PCR (49) from human GL and JEG-3 cell RNA using oligonucleotides 5Ј-ATG-AAC-TTT-CTG-CTG-TCT-TGG-GT-3Ј (157-179) and 5Ј-TCA-CCG-CCT-CGG-CTT-GTC-AC-3Ј (785-804), designed according to Sharkey et al. (44) with numbering according to Keck et al. (13) . RT reactions were performed as previously described (43) , and the cycling conditions for PCR were as follows: denaturing at 95 C for 30 sec, annealing at 55 C for 30 sec, and elongation at 72 C for 90 sec, with 45 cycles. The reagents for the PCR were purchased from Perkin-Elmer/Cetus Corp. (Norwalk, CT) and used according to the manufacturer's instructions. Southern blots for amplified VEGF cDNA fragments were prepared as previously described (50) . The cDNAs encoding VEGF 121 and VEGF 165 were ligated to the pGEM-T vector (Promega, Madison, WI) and verified by sequencing the double stranded plasmid templates using cloned T7 DNA polymerase (Sequenase 2.0, U.S. Biochemical Corp., Cleveland, OH).
Labeling of cDNA probes and hybridizations
As probes for filter hybridizations we used a human 581-bp VEGF cDNA [nucleotides (nt) 57-638) (13), VEGF-B cDNA (nt 1-382) (34) , and VEGF-C cDNA (nt 495-1661) (35) . Human cyclophilin (51) or rat glyceraldehyde-6-phosphate dehydrogenase (GAPDH) (52) cDNAs were used as controls for even loading in the filter hybridizations. All cDNA inserts were labeled with [␣-
32 P]deoxy-CTP (3000 Ci/mmol; Amersham) and a Prime-a-Gene kit (Promega). The probes were purified with nick columns (Pharmacia, Uppsala, Sweden) and used at 1-3 ϫ 10 6 dpm/ml in hybridization solution containing 50% formamide, 6 ϫ SSC, 0.1%
Expression of VEGF mRNAs in stimulated human GL cells. GL cells were first cultured for 6 (A) or 3 days (B) in medium containing 10% FCS. In A, GL cells were treated with 30 ng/ml rhFSH, 30 ng/ml hCG, 1.0 M PGE 2 , or 1.0 mM 8-Br-cAMP in 2.5% FCScontaining medium for 2 h; thereafter, 11.5 g total RNA were extracted for Northern analysis. In B, GL cells were treated for 8 h with 10 ng/ml TPA, 100 ng/ml hCG, or simultaneously with TPA and hCG. For the Northern blots, a total of 11 g cytoplasmic RNA/lane was extracted. The filters were probed with 32 P-labeled VEGF and cyclophilin cDNAs. The migrations of 28S and 18S ribosomal RNAs are shown.
FIG. 3. The effect of cell culture age on VEGF mRNA levels in untreated and stimulated human GL cells. Treatments were performed on the indicated culture days with 30 ng/ml hCG (A) or 0.5 mM 8-Br-cAMP or 10 ng/ml TPA (B) for 8 h, or with 1 M PGE 2 (C) for 2 h. Cytoplasmic RNA was analyzed by dot blot hybridization with the probe for VEGF and quantified as detailed in Materials and Methods. The data were normalized to the values of cyclophilin or GAPDH that were used as loading controls. Asterisks denote a significant induction vs. control levels on respective culture days (P Ͻ 0.05, by Student's t test).
Ficoll, 0.1% polyvinylpyrrolidone, 0.1% BSA, 100 g/ml salmon sperm DNA, 100 g/ml yeast RNA, and 0.5% SDS. Dot, Northern, and Southern blots were hybridized for 16 h at 42 C and washed three times for 20 min each time with 1 ϫ SSC-0.1% SDS at 50 C. Filters were exposed to Fuji RX x-ray film (Fuji, Tokyo, Japan) with Trimax 16T intensifying screens (3 M, Ferrania, Italy) at Ϫ70 C. The relative densities of dot blot hybridization signals were determined using a transmission densitometer (model 331, X-rite Co., Grand Rapids, MI). Alternatively, Fujifilm IP-Reader Bio-Imaging Analyzer BAS 1500 (Fuji Photo Co., Tokyo, Japan) was used to analyze hybridization filters with the MacBas software supplied by the manufacturer using a Macintosh (Apple Computer, Cupertino, CA) personal computer.
Analysis of RNA data
For single comparisons between untreated and hormone stimulated cultures, the data were analyzed using Student's t test. For multiple comparisons, the data were first analyzed by one-way ANOVA, and 
Results
Expression of VEGF splicing variants in human GL cells
The expression of VEGF mRNAs in human GL cells was first studied by Northern blot analysis of total RNA extracted from freshly isolated human GL cells. Transcripts of approximately 4.5 and 3.7 kilobases (kb) were detected for VEGF (Fig. 1A) . To characterize the alternatively spliced VEGF transcripts in human GL cells, we generated cDNA fragments by RT-PCR and analyzed the cDNAs by Southern blotting using a 581-bp VEGF 189 cDNA as a probe. Figure 1B schematically shows the locations of the exonic regions in the cDNA that encode for the five different VEGF forms. Southern blotting analyses indicated that in addition to the 121-, 145-, and 165-aa forms found in GL cells, the JEG-3 cells also expressed VEGF 189 . and then stimulated with 100 ng/ml hCG (A), 1.0 mM cAMP or 10 ng/ml TPA (B), and 1.0 M PGE 2 (C) for the indicated time periods. The samples were processed as detailed in Fig. 3 . Asterisks denote a significant increase in VEGF mRNA levels (P Ͻ 0.05, by Student's t test). For concentration dependence studies (D-F), the cells were first cultured for 6 days (D and F) or 7 days (E) and then treated for 8 h with increasing concentrations of hCG (1-100 ng/ml), 8-Br-cAMP (0.01-1 mM), or TPA (0.1-100 ng/ml). The samples were processed as detailed in Fig. 3 . Asterisks denote a significant induction vs. control levels (P Ͻ 0.05, by Scheffe's multiple comparisons test after one-way ANOVA).
Hormonal regulation of VEGF mRNA levels in cultured GL cells
To investigate whether VEGF mRNAs are hormonally regulated, we treated cultured GL cells with rhFSH, hCG, PGE 2 , 8-Br-cAMP, or the active phorbol ester TPA and analyzed VEGF transcript levels by Northern blot hybridization. Figure 2, A and B, show that all these effectors increased the expression levels of the VEGF transcripts. Simultaneous treatment with TPA and hCG did not increase VEGF levels compared with the effect of TPA treatment alone (Fig. 2B) .
Dot blot hybridization was used to characterize in more detail the dependence of VEGF mRNA expression on the culture stage used as well as the concentration and time dependence of the inductions. Figure 3 shows that basal VEGF mRNA levels declined steadily in all individual experiments during the 2-to 10-day culture period. An 8-h treatment with hCG, 8-Br-cAMP, or TPA induced VEGF transcript levels significantly [P Ͻ 0.05; by hCG on days 5, 7, and 10 of culture (Fig. 3A) and by 8-Br-cAMP or TPA on days 4, 7, and 9 of culture (Fig. 3B) ]. Treatment with PGE 2 for 2 h raised VEGF transcripts significantly on days 2, 4, and 7 of culture (Fig. 3C) . Time-course studies indicated that VEGF mRNA levels were induced only 2 or 3 h after treatment (Figs. 4, A-C) . Moreover, 2-and 6-h treatments with 100 ng/ml rhFSH induced significantly VEGF mRNA levels on day 7 of culture (data not shown). Figure 4 , D-F, shows the concentration dependence of the induction of VEGF mRNA levels by hCG, 8-Br-cAMP, and TPA. Maximal responses were observed with 10 -100 ng/ml hCG, 0.3-1 mm 8-BrcAMP, and 10 -100 ng/ml TPA. rhFSH and PGE 2 also induced VEGF mRNA levels in a dose-dependent manner, with the maximal inductive effect for rhFSH at 30 -300 ng/ml and that for PGE 2 at 0.3-1 mm (data not shown).
VEGF-B and VEGF-C mRNAs are expressed in human GL cells
As recent studies indicated that the expression of VEGF-B and VEGF-C is detected in human ovarian tissue Northern blots (34 -36), we studied whether human GL cells are able to express the mRNAs. We detected 1.4-and 2.4-kb transcripts for VEGF-B and VEGF-C, respectively, in freshly isolated GL cells using Northern blot hybridization analysis (Fig. 5, A and B) .
Regulation of VEGF-C mRNA levels by hCG and 8-Br-cAMP in cultured GL cells
To study whether VEGF-B and VEGF-C mRNAs are hormonally regulated, dot blot hybridization with specific probes was carried out to determine whether any of the effectors regulating VEGF mRNA levels would affect the transcript levels of these two genes in cultured GL cells. VEGF-B mRNAs were not found to be regulated by any hormonal treatment tested. By contrast, hCG treatment of the cells appeared to decrease VEGF-C mRNA steady state levels. Figure 5C shows that a 24-h treatment with 100 ng/ml hCG decreased VEGF-C transcript levels moderately on day 5 and more clearly on day 7 of culture, whereas the steady state mRNA levels of VEGF were induced by hCG in the same experiment. Dot blot data from the same experiment (Figs. 5C and 6A represent the Northern blot and dot blot data, respectively, from the same experiment) and those from another experiment indicated that VEGF-C mRNA levels were significantly inhibited (P Ͻ 0.05) by hCG between days 4 -7 of culture (Fig. 6, A and B) . The basal VEGF-C mRNA levels tend to rise during the culture. In the experiment represented in Fig. 6A , there was a significant (P Ͻ 0.05) difference between day 2 vs. day 5 as well as between day 5 vs. day 7 control values. Figure 6 , C and D, shows that hCG clearly decreased VEGF-C mRNA levels in a concentration-dependent manner. Time dependence studies performed on days 4 -7 of culture showed that although VEGF-C mRNA levels were decreased in some experiments as early as 3 h after hCG 2) were used for preparing Northern blots. In C, GL cells were cultured for the indicated days. The cells were then stimulated with 100 ng/ml hCG for 24 h, and 15 g total GL cell RNA were extracted and analyzed by Northern blot hybridizations probed with a mixture of 32 P-labeled VEGF, VEGF-B, and VEGF-C cDNAs. GAPDH transcripts are shown as a control for even loading.
treatment, the effect was statistically significant (P Ͻ 0.05) in all individual experiments at the 24 to 48 h points (Fig. 7 , A-C). As hCG increases intracellular cAMP levels in human GL cells, we tested whether a cell-permeable cAMP analog, 8-Br-cAMP, is also able to decrease VEGF-C mRNA levels in these cells. Figure 7 , D-F, shows three parallel experiments indicating that stimulation with 0.5-1.0 mmol/liter 8-BrcAMP decreased VEGF-C mRNA levels in GL cells with essentially similar kinetics as hCG.
Discussion
In this study we examined the expression of VEGF, VEGF-B, and VEGF-C mRNAs in human GL cells obtained from women undergoing IVF. The present study identifies ovarian GL cells as a novel site of VEGF-B and VEGF-C expression. We also investigated the regulation of the steady state levels of their mRNAs in cultured GL cells and demonstrate that VEGF and VEGF-C mRNAs are differentially regulated by hormones in these cells.
The VEGF gene consists of eight exons, and as a result of alternative splicing, different transcripts encoding VEGF forms have been identified (17) (18) (19) . We show that VEGF transcripts giving rise to VEGF 121 , VEGF 145 , and VEGF 165 are produced in human GL cells. Furthermore, four alternatively spliced VEGF transcripts were identified in JEG-3 choriocarcinoma cells. These data are well in line with the earlier observations of others who detected splicing variants representing 121-, 145-, 165-, and 189-aa VEGF forms in human endometrium, myometrium, and endometrial carcinoma cell lines (19, 44). As no information has been available on the expression of VEGF 145 other than in the endometrium and choriocarcinoma cells (19, 44) or in human epithelial ovarian carcinoma cells (20), the present study identifies the ovarian GL cell as a novel site for the expression of this isoform. The expression of alternatively spliced VEGF forms appear to be regulated in tissue-specific manner (18, 19) . As VEGF 121 and VEGF 165 are known to have different receptor binding abilities (53), other alternatively spliced VEGF forms may have distinct, as yet unknown, biological effects.
The present study demonstrates that hCG and rhFSH induce VEGF mRNA levels in human GL cells. The VEGF mRNAs were clearly enhanced by hCG on day 5 of culture. At the beginning of the culture, human GL cells may be desensitized to gonadotropins because they are derived from hyperstimulated IVF patients (54) . This is likely to explain why gonadotropin treatment was not able to increase VEGF mRNA levels during the early stages of culture. Using this cell culture model, we observed the same phenomenon for several gonadotropin-regulated hormonal parameters (51, (55) (56) (57) . Our data on the stimulatory effect of hCG on VEGF mRNA levels are in line with the observations of Ravindranath et al. (27) , suggesting that LH mediates the induction of VEGF expression in primate CL. As hCG stimulates human GL cells through the hCG/LH receptor, which binds both hCG and LH with high affinity (58), it is likely that LH is acting in a similar manner as hCG in GL cells. Similar to our results, Neulen et al. showed recently that hCG induces VEGF mRNA levels in cultured human GL cells (28). In contrast to their observations, we detected a clear increase in VEGF mRNAs when the cells were treated with rhFSH on days 5-7 of culture. This difference may be explained by the delayed responsiveness to rhFSH, compared with that to hCG, which is characteristic of this cell culture system (59) . Our data clearly indicate that stimulation of both the FSH   FIG. 6 . The effects of cell culture age on basal and hCG-stimulated VEGF-C mRNA levels (A and B) and the effect of increasing concentrations of hCG on VEGF-C mRNA levels (C and D) in cultured human GL cells. Two parallel experiments are shown. In A and B, the cells were first cultured for the indicated days and then stimulated with 100 ng/ml hCG for 24 h (A represents dot blot data of the same experiment as that in Fig. 5C ). Cytoplasmic RNA was analyzed by dot blot hybridization with a 32 P-labeled VEGF-C cDNA probe, followed by densitometric scanning of autoradiographs. In C and D, the cells were cultured for 4 (C) or 5 (D) days and then treated with increasing concentrations of hCG (1-100 ng/ml) for 24 h (C) or 8 h (D). The samples were processed as indicated above. Asterisks denote a significant (P Ͻ 0.05) decrease vs. control levels.
and LH/hCG receptor-activated pathways is able to induce VEGF mRNA levels in human GL cells.
The time-course studies indicated that hCG, 8-Br-cAMP, TPA, and PGE 2 induced VEGF mRNA levels rapidly in cultured human GL cells, which is consistent with the results obtained with granulosa cells of human origin (28) and from other species (29, 60) as well as with other types of cells (30, 61) demonstrating that VEGF transcript levels are regulated as early as 1 h after treatment. Our results also show that the basal levels of VEGF mRNAs decreased during the culture period. Interestingly, in human ovarian sections, immunoreactivity for VEGF was found in highly vascularized CL, but not in degenerating CL (62) .
A recent study has demonstrated that there are several potential activating protein-1-and -2-binding sites in the human VEGF gene promoter sequence, suggesting that both cAMP and TPA could induce transcription of the VEGF gene (17) . The present data are consistent with these findings. We show that both 8-Br-cAMP and TPA are potent inducers of VEGF mRNA levels in cultured human GL cells. In bovine granulosa cell cultures, forskolin, an adenylate cyclase activator, and TPA have also been shown to induce VEGF mRNA levels (29). PGE 2 has been found to be effective in enhancing VEGF mRNA levels in rat osteoblast and human synovial fibroblast cell cultures (30, 61). We show here that PGE 2 increases VEGF mRNAs also in cultured human GL cells. Although the receptor isotypes binding PGE 2 in these cells have not been characterized, it is possible that PGE 2 may mediate this effect through a protein kinase A-dependent signaling pathway, as PGE 2 increases cAMP levels in human granulosa cells (63) .
VEGF-B is widely expressed in various tissues, most prominently in heart, skeletal muscle, and the pancreas (34) . A recent study has further indicated that VEGF-B and VEGF-C might be important regulators of the reproductive system, as VEGF-B and VEGF-C mRNAs are highly expressed in human placenta (64) . We show here that VEGF-B is expressed in human GL cells, and its expression level is rather stable in primary cultures of these cells. However, in contrast to VEGF and VEGF-C, VEGF-B mRNA levels were not found to be regulated by any hormonal treatment in vitro. As VEGF-B heterodimerized with VEGF when coexpressed in human embryo kidney, 293EBNA, cells (34) , the overlapping expression of VEGF and VEGF-B in human GL cells suggests that these cells may produce natural VEGF-VEGF-B heterodimers. As VEGF 165 -VEGF-B heterodimers, in the absence of heparin, remain cell associated, VEGF-B may affect the bioavailability of VEGF.
VEGF-C transcripts are readily expressed in freshly isolated human GL cells, and hCG appears to decrease their steady state levels. In contrast to VEGF, the basal steady state expression of VEGF-C mRNAs is enhanced in GL cells during culture. During early stages of culture, the low levels of VEGF-C and the increased levels of VEGF may reflect the fact that these cells have been exposed in vivo to large doses of gonadotropins before oocyte harvest. As the cells regain their responsiveness to hCG by days 4 -5 of culture, VEGF-C levels spontaneously increase, whereas VEGF mRNA levels continuously decrease. Interestingly, the expression pattern of basal VEGF-C mRNA resembles that of another granulosa cell-derived growth factor, bone morphogenetic protein-3, which is regulated in a similar manner by hCG (57) . Our data indicate that after day 4 of culture, VEGF-C mRNA steady state levels are suppressed by hCG in a concentration-and time-dependent manner. We further show that 8-Br-cAMP decreases VEGF-C mRNAs in GL cells in a similar manner as hCG. Thus, we conclude that VEGF and VEGF-C transcript levels are differentially regulated and suggest that the protein kinase A signaling pathway may be responsible for these effects of hCG.
It is possible that VEGF, VEGF-B, and VEGF-C regulate angiogenesis in the CL. The present study shows that human GL cells express VEGF, VEGF-B, and VEGF-C mRNAs and that their expression is regulated differentially in vitro. Further studies are required to clarify the biological roles and cellular targets of these three growth factors in the ovary. 
